BridgeBio Pharma, Inc. (BBIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, BridgeBio Pharma reported revenue of $502.1M, up 126.3% from $221.9M the year before. Net income was -$724.9M (a -144.4% net margin), or -$3.78 per diluted share. Gross margin was 95.8% and operating margin was -104.2%. Operating activities generated -$445.9M of cash, leaving -$447.0M of free cash flow. At fiscal year end, BridgeBio Pharma held $936.0M in total assets against $3.01B in total liabilities, including $570.1M of cash and equivalents.
Open the full interactive BridgeBio Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
BridgeBio Pharma Key Stats
| Share Price | $63.30 |
|---|---|
| Market Cap | $12.39B |
| Revenue YoY Growth | +126.3% |
| 52-Week Range | $53.24 – $90.17 |
| Shares Outstanding | 195.8 million (basic, 2026 Q2) |
BridgeBio Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Cost of Goods Sold | — | $2.7M | $589.9M | $616.7M | $814.9M | $1.03B |
| Gross Profit | — | $67.0M | -$512.2M | $6.9M | $218.0M | $481.1M |
| Operating Income | -$474.5M | -$576.6M | -$512.2M | -$607.4M | -$593.0M | -$523.4M |
| Pre-Tax Income | $505.5M | -$586.5M | -$484.7M | -$653.3M | -$542.2M | -$732.5M |
| Income Tax | $954.2M | -$23.9M | -$3.5M | -$10.0M | $1.2M | $435,000 |
| Net Income | -$448.7M | -$562.5M | -$481.2M | -$643.2M | -$535.8M | -$724.9M |
| Diluted EPS | -$3.80 | -$3.90 | -$3.26 | -$3.95 | -$2.88 | -$3.78 |
BridgeBio Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $120.7M | $154.2M | $194.5M | $243.7M |
| Net Income | -$182.7M | -$192.9M | -$164.0M | -$152.2M |
| Diluted EPS | -$0.95 | -$1.01 | -$0.84 | -$0.78 |
BridgeBio Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $356.1M | $393.8M | $376.7M | $375.9M | $681.1M | $570.1M |
| Current Assets | $642.8M | $888.9M | $548.9M | $477.6M | $720.7M | $797.7M |
| Total Assets | $703.6M | $1.01B | $623.0M | $546.4M | $919.3M | $936.0M |
| Current Liabilities | $95.6M | $135.1M | $121.4M | $143.8M | $154.4M | $288.0M |
| Total Long-Term Debt | $93.9M | $430.8M | $431.0M | $446.4M | $437.3M | $2.01B |
| Total Liabilities | $595.7M | $1.88B | $1.87B | $1.89B | $2.38B | $3.01B |
| Shareholders' Equity | $57.9M | -$870.4M | -$1.25B | -$1.35B | -$1.47B | -$2.09B |
BridgeBio Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$399.7M | -$497.9M | -$419.5M | -$527.7M | -$520.7M | -$445.9M |
| Cash From Investing | -$53.0M | -$200.8M | $453.1M | $54.0M | $60.8M | -$24.5M |
| Cash From Financing | $447.2M | $736.4M | -$13.1M | $451.5M | $748.5M | $359.3M |
| Free Cash Flow | -$407.2M | -$511.2M | -$424.3M | -$529.0M | -$521.7M | -$447.0M |
Figures from BridgeBio Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BridgeBio Pharma financials page for every line item.
BridgeBio Pharma Company Profile
| Ticker | BBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Palo Alto, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001743881 |
Frequently Asked Questions
What was BridgeBio Pharma's revenue in fiscal 2025?
BridgeBio Pharma (BBIO) reported revenue of $502.1M for fiscal 2025.
What is BridgeBio Pharma's annual revenue history?
BridgeBio Pharma's annual revenue by fiscal year: 2020: $8.2M; 2021: $69.7M; 2022: $77.6M; 2023: $9.3M; 2024: $221.9M; 2025: $502.1M.
What was BridgeBio Pharma's net income in fiscal 2025?
BridgeBio Pharma reported net income of -$724.9M for fiscal 2025.
What was BridgeBio Pharma's earnings per share (EPS) in fiscal 2025?
BridgeBio Pharma's diluted EPS was -$3.78 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did BridgeBio Pharma generate in fiscal 2025?
BridgeBio Pharma generated -$447.0M of free cash flow in fiscal 2025.
What was BridgeBio Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), BridgeBio Pharma reported revenue of $243.7M.
How much debt does BridgeBio Pharma have?
BridgeBio Pharma reported $2.01B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of BridgeBio Pharma are outstanding?
BridgeBio Pharma reported a weighted average of 195.8 million basic shares outstanding in 2026 Q2.
What is BridgeBio Pharma's market cap?
Based on its latest closing price, BridgeBio Pharma (BBIO) has a market capitalization of about $12.39B.
When does BridgeBio Pharma's fiscal year end?
BridgeBio Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma lists its business address in Palo Alto, California in its SEC filings.